Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn’s Disease

INTRODUCTION: Risankizumab (RZB) and ustekinumab (UST), interleukin (IL)-23 and IL-12/23 inhibitors, respectively, are approved treatments for moderately to severely active Crohn’s disease (CD); direct comparison between the two is ongoing. We indirectly compared efficacy of RZB versus UST using dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubinsky, Marla, Ma, Christopher, Griffith, Jenny, Crowell, Marjorie, Neimark, Ezequiel, Kligys, Kristina, O’Connell, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427520/
https://www.ncbi.nlm.nih.gov/pubmed/37368103
http://dx.doi.org/10.1007/s12325-023-02546-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427520/
https://www.ncbi.nlm.nih.gov/pubmed/37368103
http://dx.doi.org/10.1007/s12325-023-02546-6

Ejemplares similares